Basophils and autoreactive ige in the pathogenesis of systemic lupus erythematosus

Current Allergy and Asthma Reports

Volumn 11, Issue 5, 2011, Pages 378-387

  Charles, Nicolas ^a   Rivera, Juan ^b  

^a INSERM   (France)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Autoantibody; Basophils; IgE; IL 4; Interleukin 4; Lupus; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; AUTOREACTIVE IMMUNOGLOBULIN E; FC EPSILON RECEPTOR I; FC RECEPTOR; IMMUNOGLOBULIN E; PROTEIN KINASE LYN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BASOPHIL; CELL FUNCTION; CELL SURVIVAL; DISEASE ASSOCIATION; DISEASE MODEL; ENZYME ACTIVITY; EXPERIMENTAL ANIMAL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE FUNCTION; NONHUMAN; PHENOTYPE; SYSTEMIC LUPUS ERYTHEMATOSUS; TH2 CELL;

ANIMALS; ANTIBODY FORMATION; AUTOANTIBODIES; BASOPHILS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN E; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTES; MICE;

EID: 81055140539     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-011-0216-5     Document Type: Article

References (59)

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929-39. (Pubitemid 351397092)
2. Perry D, Sang A, Yin Y, et al. Murine models of systemic lupus erythematosus. J Biomed Biotechnol. 2011;2011:271694.
3. Sobel ES, Satoh M, Chen Y, et al. The major murine systemic lupus erythematosus susceptibility locus Sle1 results in abnormal functions of both B and T cells. J Immunol. 2002;169:2694-700. (Pubitemid 34921018)
4. Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev. 1999;169:107-21. (Pubitemid 29338727)
5. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol. 2001;2:764-6.
6. Calero I, Sanz I. Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning? Discov Med. 2010;10:416-424.
7. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721-31.
8. Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs. 2010;70:529-40.
9. Davidson A. Targeting BAFF in autoimmunity. Curr Opin Immunol. 2010;22:732-9.
10. Peng SL, Szabo SJ, Glimcher LH. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci USA. 2002;99:5545-50. (Pubitemid 34411585)
11. Mangini AJ, Lafyatis R, Van Seventer JM. Type I interferons inhibition of inflammatory T helper cell responses in systemic lupus erythematosus. Ann N YAcad Sci. 2007;1108:11-23. (Pubitemid 47528714)
12. Charles N, Hardwick D, Daugas E, et al. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med. 2010;16:701-7.
13. Ronnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus. 2008;17:394-9. (Pubitemid 351798715)
14. Monk CR, Spachidou M, Rovis F, et al. MRL/Mp CD4+, CD25- T cells show reduced sensitivity to suppression by CD4+, CD25+ regulatory T cells in vitro: a novel defect of T cell regulation in systemic lupus erythematosus. Arthritis Rheum. 2005;52:1180-4. (Pubitemid 40530125)
15. Miyara M, Amoura Z, Parizot C, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol. 2005;175:8392-400. (Pubitemid 41798406)
16. Nagpal S, Sriramarao P, Krishnaswamy PR, et al. Demonstration of IgE antibodies to nucleic acid antigens in patients with SLE. Autoimmunity. 1990;8:59-64.
17. Permin H, Wiik A. The prevalence of IgE antinuclear antibodies in rheumatoid arthritis and systemic lupus erythematosus. Acta Pathol Microbiol Scand C. 1978;86C:245-9. (Pubitemid 9043749)
18. Atta AM, Sousa CP, Carvalho EM, et al. Immunoglobulin E and systemic lupus erythematosus. Braz J Med Biol Res. 2004;37:1497-501. (Pubitemid 39369037)
19. Oxelius VA, Immunoglobulin G. (IgG) subclasses and human disease. Am J Med. 1984;76:7-18.
20. Kingsmore SF, Thompson JM, Crockard AD, et al. Measurement of circulating immune complexes containing IgG, IgM, IgA and IgE by flow cytometry: correlation with disease activity in patients with systemic lupus erythematosus. J Clin Lab Immunol. 1989;30:45-52. (Pubitemid 20299229)
21. Elkayam O, Tamir R, Pick AI, et al. Serum IgE concentrations, disease activity, and atopic disorders in systemic lupus erythematosus. Allergy. 1995;50:94-6.
22. Sequeira JF, Cesic D, Keser G, et al. Allergic disorders in systemic lupus erythematosus. Lupus. 1993;2:187-91. (Pubitemid 23225637)
23. Wozniacka A, Sysa-Jedrzejowska A, Robak E, et al. Allergic diseases, drug adverse reactions and total immunoglobulin E levels in lupus erythematosus patients. Mediators Inflamm. 2003;12:95-9. (Pubitemid 36783248)
24. Sekigawa I, Yoshiike T, Iida N, et al. Allergic diseases in systemic lupus erythematosus: prevalence and immunological considerations. Clin Exp Rheumatol. 2003;21:117-21. (Pubitemid 36267545)
25. Karasuyama H, Mukai K, Obata K, et al. Nonredundant roles of basophils in immunity. Annu Rev Immunol. 2011;29:45-69.
26. Denzel A, Maus UA, Rodriguez Gomez M, et al. Basophils enhance immunological memory responses. Nat Immunol. 2008;9:733-42. (Pubitemid 351859156)
27. Oh K, Shen T, Le Gros G, et al. Induction of Th2 type immunity in a mouse system reveals a novel immunoregulatory role of basophils. Blood. 2007;109:2921-7. (Pubitemid 46482089)
28. Hida S, Tadachi M, Saito T, et al. Negative control of basophil expansion by IRF-2 critical for the regulation of Th1/Th2 balance. Blood. 2005;106:2011-7. (Pubitemid 41291714)
29. Sokol CL, Barton GM, Farr AG, et al. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Immunol. 2008;9:310-8. (Pubitemid 351267328)
30. Charles N, Watford WT, Ramos HL, et al. Lyn kinase controls basophil GATA-3 transcription factor expression and induction of Th2 cell differentiation. Immunity. 2009;30:533-43.
31. Perrigoue JG, Saenz SA, Siracusa MC, et al. MHC class IIdependent basophil-CD4+ T cell interactions promote T(H)2 cytokine-dependent immunity. Nat Immunol. 2009;10:697-705.
32. Yoshimoto T, Yasuda K, Tanaka H, et al. Basophils contribute to T (H)2-IgE responses in vivo via IL-4 production and presentation of peptide-MHC class II complexes to CD4+ T cells. Nat Immunol. 2009;10:706-12.
33. Sokol CL, Chu NQ, Yu S, et al. Basophils function as antigenpresenting cells for an allergen-induced T helper type 2 response. Nat Immunol. 2009;10:713-20.
34. Rodriguez GomezM, Talke Y, Goebel N, et al. Basophils support the survival of plasma cells in mice. J Immunol. 2010;185:7180-5.
35. Mukai K, Matsuoka K, Taya C, et al. Basophils play a critical role in the development of IgE-mediated chronic allergic inflammation independently of Tcells and mast cells. Immunity. 2005;23:191-202. (Pubitemid 41169288)
36. Ohnmacht C, Schwartz C, Panzer M, et al. Basophils orchestrate chronic allergic dermatitis and protective immunity against helminths. Immunity. 2010;33:364-74.
37. Tang H, Cao W, Kasturi SP, et al. The T helper type 2 response to cysteine proteases requires dendritic cell-basophil cooperation via ROS-mediated signaling. Nat Immunol. 2010;11:608-17.
38. Hibbs ML, Harder KW. The duplicitous nature of the Lyn tyrosine kinase in growth factor signaling. Growth Factors. 2006;24:137-49.
39. Yamanashi Y, Mori S, Yoshida M, et al. Selective expression of a protein-tyrosine kinase, p56lyn, in hematopoietic cells and association with production of human T-cell lymphotropic virus type I. Proc Natl Acad Sci USA. 1989;86:6538-42. (Pubitemid 19236313)
40. DeFranco AL, Chan VW, Lowell CA. Positive and negative roles of the tyrosine kinase Lyn in B cell function. Semin Immunol. 1998;10:299-307. (Pubitemid 28375305)
41. Janas ML, Hodgkin P, Hibbs M, et al. Genetic evidence for Lyn as a negative regulator of IL-4 signaling. J Immunol. 1999;163:4192-8. (Pubitemid 29474482)
42. Wang J, Koizumi T, Watanabe T. Altered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient mice. J Exp Med. 1996;184:831-8.
43. Parravicini V, Gadina M, Kovarova M, et al. Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat Immunol. 2002;3:741-8.
44. Odom S, Gomez G, Kovarova M, et al. Negative regulation of immunoglobulin E-dependent allergic responses by Lyn kinase. J Exp Med. 2004;199:1491-502. (Pubitemid 38780404)
45. Yamashita Y, Charles N, Furumoto Y, et al. Cutting edge: genetic variation influences Fc epsilonRI-induced mast cell activation and allergic responses. J Immunol. 2007;179:740-3.
46. Baran CP, Tridandapani S, Helgason CD, et al. The inositol 5'- phosphatase SHIP-1 and the Src kinase Lyn negatively regulate macrophage colony-stimulating factor-induced Akt activity. J Biol Chem. 2003;278:38628-36. (Pubitemid 37221760)
47. Harder KW, Parsons LM, Armes J, et al. Gain- and loss-offunction Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Immunity. 2001;15:603-15. (Pubitemid 33016445)
48. Hibbs ML, Tarlinton DM, Armes J, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell. 1995;83:301-11.
49. Nishizumi H, Taniuchi I, Yamanashi Y, et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyndeficient mice. Immunity. 1995;3:549-60.
50. Flores-Borja F, Kabouridis PS, Jury EC, et al. Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:3955-65. (Pubitemid 41798235)
51. Lu R, Vidal GS, Kelly JA, et al. Genetic associations of LYN with systemic lupus erythematosus. Genes Immun. 2009;10:397-403.
52. Eiseman E, Bolen JB. Engagement of the high-affinity IgE receptor activates src protein-related tyrosine kinases. Nature. 1992;355:78-80.
53. Beavitt SJ, Harder KW, Kemp JM, et al. Lyn-deficient mice develop severe, persistent asthma: Lyn is a critical negative regulator of Th2 immunity. J Immunol. 2005;175:1867-75. (Pubitemid 41023093)
54. Hernandez-Hansen V, Smith AJ, Surviladze Z, et al. Dysregulated FcepsilonRI signaling and altered Fyn and SHIP activities in Lyndeficient mast cells. J Immunol. 2004;173:100-12. (Pubitemid 38797331)
55. Damen JE, Ware MD, Kalesnikoff J, et al. SHIP's C-terminus is essential for its hydrolysis of PIP3 and inhibition of mast cell degranulation. Blood. 2001;97:1343-51. (Pubitemid 32183758)
56. Harding CV. Cellular and molecular aspects of antigen processing and the function of class II MHC molecules. Am J Respir Cell Mol Biol. 1993;8:461-7.
57. Chen K, Xu W, Wilson M, et al. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat Immunol. 2009;10:889-98.
58. Holgate S, Buhl R, Bousquet J, et al. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med. 2009;103:1098-113.
59. Ben-Shoshan M. Omalizumab: not only for asthma. Recent Pat Inflamm Allergy Drug Discov. 2008;2:191-201.